Cargando…
Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles
Current treatment of glioma is hampered due to the physical blood-brain barrier (BBB) and the resistance to traditional chemotherapeutic agents. Herein, we proposed a combined treatment strategy based on Cyclo (Arg-Gly-Asp-d-Phe-Lys) (cRGDfk) peptides-modified nanoparticle named cRGD-P in a self-ass...
Autores principales: | He, Yihong, Zan, Xin, Miao, Junming, Wang, Bilan, Wu, Yin, Shen, Yangmei, Chen, Xinchuan, Gou, Hongfeng, Zheng, Songping, Huang, Ning, Cheng, Yongzhong, Ju, Yan, Fu, Xianghui, Qian, Zhiyong, Zhou, Peizhi, Liu, Jiagang, Gao, Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489811/ https://www.ncbi.nlm.nih.gov/pubmed/36157053 http://dx.doi.org/10.1016/j.mtbio.2022.100423 |
Ejemplares similares
-
A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization
por: Yang, Tingting, et al.
Publicado: (2022) -
Antibody–PROTAC Conjugates Enable HER2-Dependent
Targeted Protein Degradation of BRD4
por: Maneiro, María, et al.
Publicado: (2020) -
The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells
por: Qin, An-cheng, et al.
Publicado: (2020) -
Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells
por: Wang, Qiang, et al.
Publicado: (2023) -
A Versatile
and Sustainable Multicomponent Platform
for the Synthesis of Protein Degraders: Proof-of-Concept Application
to BRD4-Degrading PROTACs
por: Bhela, Irene Preet, et al.
Publicado: (2022)